Methods and compositions for increasing the dose of a chemotherapeutic agent
The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
1. A method for increasing the dose of a chemotherapeutic agent in a subject in need thereof, comprising administering to the subject an effective amount of a peptide having the formula D-Arg-2′6′-dimethyltyrosine-Lys-Phe-NH 2 , or a pharmaceutically acceptable salt thereof, wherein the peptide treats or prevents one or more dose-limiting neuropathic conditions induced by the chemotherapeutic agent, thereby permitting an increase in the dose of the chemotherapeutic agent.
2. The method of claim 1 , wherein the one or more dose-limiting neuropathic conditions is selected from a group consisting of myalgia, painful burning paresthesis, glove-and-stocking sensory neuropathy, hyperalgia, and allodynia.
3. The method of claim 1 , wherein the subject is a human.
4. The method of claim 1 , wherein the peptide is administered prior the onset of the one or more dose-limiting neuropathic conditions.
5. The method of claim 1 , wherein the pharmaceutically acceptable salt comprises acetate.
6. The method of claim 1 , wherein the chemotherapeutic agent is procarbazine, nitrofurazone, podophyllum, mustine, ethoglucid, cisplatin, suramin, paclitaxel, chlorambucil, altretamine, carboplatin, cytarabine, docetaxel, dacarbazine, etoposide, ifosfamide with mesna, fludarabine, tamoxifen, teniposide, thioguanine, or vincristine.
7. The method of claim 6 , wherein the chemotherapeutic agent is vincristine.
8. The method of claim 6 , wherein the peptide is administered simultaneously with the chemotherapeutic agent.
9. The method of claim 6 , wherein the peptide is administered subsequent to the chemotherapeutic agent.